A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|New England Journal of Medicine|2020Cited by 320
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Della Porta, Uwe Platzbecker, Sophie Dimicoli‐Salazar et al.|The Lancet Haematology|2024Cited by 50
Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE TrialJohn B. Porter, Alì Taher, Maria Domenica Cappellini et al.|Blood|2024Cited by 1
PREDICTING EXTUBATION FAILURE: A RETROSPECTIVE MULTIVARIABLE ANALYSISMuhammad Sameed, Carl Shanholtz, Jennie Zhang et al.|CHEST Journal|2019Cited by 0